Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
biotech
boston blog main
4
×
boston top stories
indiana blog main
indiana top stories
life sciences
national blog main
national top stories
novartis
4
×
san francisco blog main
4
×
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
fda
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
biogen
cancer
clinical trials
europe blog main
europe top stories
genentech
ipo
10x genomics
abbvie
What
fda
4
×
medicines
approval
bio
drug
new
roundup
won
activity
address
amgen
approvals
approves
august
biogen
biotech
blueprint
busy
cancer
candidates
carries
certain
clamped
class
covid
days
decisions
delays
designed
developed
developing
devices
drugs
economic
fast
genetic
gets
head
including
ipo
Language
unset
Current search:
photo
×
fda
×
" boston blog main "
×
novartis
×
" san francisco blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines